Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 6/2012

01-12-2012 | SHORT REPORT

SOCS1 is significantly up-regulated in Nutlin-3-treated p53wild-type B chronic lymphocytic leukemia (B-CLL) samples and shows an inverse correlation with miR-155

Authors: Maria Grazia di Iasio, Alessia Norcio, Elisabetta Melloni, Giorgio Zauli

Published in: Investigational New Drugs | Issue 6/2012

Login to get access

Summary

The basal SOCS1 mRNA levels were significantly lower in p53mutated BJAB and MAVER leukemic cell lines with respect to p53wild-type SKW6.4 and JVM-2 leukemic cell lines, p53wild-type primary B chronic lymphocytic leukemia (B-CLL) cells and primary normal peripheral blood mononuclear cells (PBMC). Moreover, the MDM2 small molecule inhibitor Nutlin-3 significantly increased the levels of SOCS1 mRNA in both primary p53wild-type B-CLL cells as well as in p53wild-type B leukemic cell lines, but not in p53mutated B leukemic cell lines nor in primary PBMC. Of note, a significant inverse correlation was observed between SOCS1 mRNA and miR-155 levels in Nutlin-3-treated primary B-CLL cells and PBMC, suggesting that the miRNA-155/SOCS1 axis represents a potentially important therapeutic target of Nutlin-3 in B-CLL.
Literature
1.
Secchiero P, di Iasio MG, Gonelli A, Zauli G (2008) The MDM2 inhibitor Nutlins as an innovative therapeutic tool for the treatment of haematological malignancies. Curr Pharm Des 14:2100–2110PubMedCrossRef
2.
Secchiero P, Zerbinati C, di Iasio MG et al (2007) Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells. Curr Drug Metab 8:395–403PubMedCrossRef
3.
Secchiero P, Barbarotto E, Tiribelli M et al (2006) Functional integrity of the p53-mediated apoptotic pathway induced by the non-genotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood 107:4122–4129PubMedCrossRef
4.
Saddler C, Ouillette P, Kujawski L et al (2008) Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood 111:1584–1593PubMedCrossRef
5.
di Iasio MG, Addobbati R, Radillo O, Voltan R (2011) Nutlin-3 differentially modulates miRNA34a and miRNA181 versus miR26a and miR155 in p53 proficient and p53 deficient B chronic lymphocytic leukemia (B-CLL) samples. Invest New Drugs [Epub ahead of print]
6.
Lu LF, Thai TH, Calado DP et al (2009) Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells through targeting SOCS1. Immunity 30:80–91PubMedCrossRef
7.
Jiang S, Zhang HW, Lu MH et al (2010) MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res 70:3119–3127PubMedCrossRef
8.
Alexander WS (2002) Suppressors of cytokine signalling (SOCS) in the immune system. Nat Rev Immunol 2:410–416PubMed
9.
Frantsve J, Schwaller J, Sternberg DW, Kutok J, Gilliland DG (2001) Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation. Mol Cell Biol 21:3547–3557PubMedCrossRef
10.
Reddy J, Shivapurkar N, Takahashi T et al (2005) Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors. Oncogene 24:732–736PubMedCrossRef
11.
Galm O, Yoshikawa H, Esteller M, Osieka R, Herman JG (2003) SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood 101:2784–2788PubMedCrossRef
12.
Chim CS, Wong KY, Loong F, Srivastava G (2004) SOCS1 and SHP1 hypermethylation in mantle cell lymphoma and follicular lymphoma: implications for epigenetic activation of the Jak/STAT pathway. Leukemia 18:356–358PubMedCrossRef
13.
Secchiero P, Melloni E, di Iasio MG et al (2009) Nutlin-3 upregulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feed-back anti-apoptotic mechanism. Blood 113:4300–4308PubMedCrossRef
14.
Zauli G, Re MC, Furlini G, Giovannini M, La Placa M (1992) Human immunodeficiency virus type 1 envelope glycoprotein gp120-mediated killing of human haematopoietic progenitors (CD34+ cells). J Gen Virol 73:417–421PubMedCrossRef
15.
Campioni D, Secchiero P, Corallini F et al (2005) Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes. Am J Pathol 166:557–563PubMedCrossRef
16.
Gibellini D, Bassini A, Pierpaoli S et al (1998) Extracellular HIV-1 Tat protein induces the rapid Ser133 phosphorylation and activation of CREB transcription factor in both Jurkat lymphoblastoid T cells and primary peripheral blood mononuclear cells. J Immunol 160:3891–3898PubMed
17.
Wang M, Tan L, Dijkstra M et al (2008) miRNA analysis in B-cell chronic lymphocytic leukaemia: proliferation centres characterized by low miR-150 and high BIC/miR-155 expression. J Pathol 215:13–20PubMedCrossRef
18.
Androulidaki A, Iliopoulos D, Arranz A et al (2009) The kinase Akt1 controls macrophage response to lipopolysaccharide by regulating microRNAs. Immunity 31:220–231PubMedCrossRef
19.
Jongen-Lavrencic M, Sun SM, Dijkstra MK, Valk PJ, Lowenberg B (2008) MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood 111:5078–5085PubMedCrossRef
20.
Cammarata G, Augugliaro L, Salemi D et al (2010) Differential expression of specific microRNA and their targets in acute myeloid leukemia. Am J Haematol 85:331–339
21.
Wang M, Tan LP, Dijkstra MK et al (2008) miRNA analysis in B-cell chronic lymphocytic leukaemia: proliferation centres characterized by low miR-150 and high BIC/miR-155 expression. J Pathol 215:13–20PubMedCrossRef
22.
Marton S, Garcia MR, Robello C et al (2008) Small RNAs analysis in CLL reveals a deregulation of miRNA expression and novel miRNA candidates of putative relevance in CLL pathogenesis. Leukemia 22:330–338PubMedCrossRef
Metadata
Title
SOCS1 is significantly up-regulated in Nutlin-3-treated p53wild-type B chronic lymphocytic leukemia (B-CLL) samples and shows an inverse correlation with miR-155
Authors
Maria Grazia di Iasio
Alessia Norcio
Elisabetta Melloni
Giorgio Zauli
Publication date
01-12-2012
Publisher
Springer US
Published in
Investigational New Drugs / Issue 6/2012
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-011-9786-2

Other articles of this Issue 6/2012

Investigational New Drugs 6/2012 Go to the issue

PRECLINICAL STUDIES

Assessment of the novel tubulin-binding agent EHT 6706 in combination with ionizing radiation or chemotherapy

PHASE I STUDIES

Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies

PHASE I STUDIES

Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors

OriginalPaper

Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer

PRECLINICAL STUDIES

Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models

PRECLINICAL STUDIES

Pretargeting of necrotic tumors with biotinylated hypericin using 123I-labeled avidin: evaluation of a two-step strategy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits